Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.57 |
| ▸ | CDK4 | P11802 | 4/20 | 0.57 |
| ▸ | CDK1 | P06493 | 1/20 | 0.57 |
| ▸ | IKBKB | O14920 | 8/20 | 0.55 |
| ▸ | CHUK | O15111 | 4/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3253045 | 0.95 | CDK2 (0.61) | CDK2CDK4CDK1IKBKBCHUK | |
| SCHEMBL3251653 | 0.86 | CDK2 (0.58) | CDK2CDK4CDK1IKBKBCHUK | |
| SCHEMBL3250044 | 0.81 | CDK1 (0.59) | CDK2CDK4CDK1 | |
| SCHEMBL3247683 | 0.80 | CDK2 (0.61) | CDK2CDK4CDK1IKBKBCHUK | |
| SCHEMBL6593918 | 0.77 | CDK2 (0.90) | CDK2CDK4CDK1CCNT1CDK9 | |
| SCHEMBL6599298 | 0.75 | CDK2 (0.67) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL6106428 | 0.75 | CDK2 (0.90) | CDK2CDK4CDK1CCNT1CDK9 | |
| SCHEMBL4817051 | 0.75 | CDK2 (0.72) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL6595584 | 0.75 | CDK2 (0.78) | CDK2CDK4CDK1 | |
| SCHEMBL6295111 | 0.75 | CDK2 (0.68) | CDK2CDK4CDK1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | claimed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | claimed |
| EP-1896470-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-03-12 | — | — | EP | claimed |
| WO-2006124863-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-11-23 | — | — | WO | claimed |
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| EP-1896470-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006124863-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | ERBB2, JAK2, AURKC | CDK2 9/4885CDK4 129/4885CDK1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.